Numerous business, research and funding relationships have achieved significant momentum. The Company is leveraging its expertise, knowledge and multiple opportunities into the mainstream investment community in order to accelerate the pace of activity towards commercialization.
Notable Current Stakeholders in SGN Nanopharma
Novavax Inc. (Nasdaq Listed, NVAX; Market Cap $2B)
Sunways (India), Private Ltd – Our lead formulation, MNP Nanocyclosporine (preservative containing) for dry eye, “NanoTearsTM”, was launched in India in April, 2015 and has been the fastest growing brand in the Cyclosprine Ophthalmic segment rising to become the 3rd largest selling product within three years of its launch. Enabled by SGN’s proprietary MNP platform, Sunways has been able to penetrate the highly competitive market in India and managed to establish a strong position amongst leading ophthalmic companies. The strength of our technology and its superior design are key elements that have been rewarded by the market helping SGN firmly establish a foothold in a highly crowded and competitive landscape in India. According to a physician survey Nano Tears provided relief to over 75% of patients in 4 weeks, with non-significant reports of side effects.
Medicom Healthcare – Encouraged by the performance of Nano Tears, SGN has invested in the development of the next generation, preservative free, multi-dose vial packaged, MNP Nanocyclosporine and, we have signed a 15-year exclusive marketing agreement with Medicom Healthcare. Medicom, based in the UK, is a fast-growing ophthalmic company, 3rd largest in United Kingdom with presence in over 20 countries in Europe, South East Asia and is about to enter the US market. Medicom is set to launch the first ever preservative free multi dose MNP Nanocyclosporine formulation in India under the brand “Evolve Cyclo MNP”.
Ongoing Late-Stage Partnership Discussions in India
Several ongoing and in some instances, late-stage.